{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:02:23Z","timestamp":1792252943533,"version":"4.4.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>In this report, we determined the efficacy and the toxicity of low dose weekly gemcitabine with radiotherapy, in medically unfit or refused surgery muscle-invasive bladder cancer (BC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      From 2008 to 2012, 15 patients were included into the retrospective analysis. Weekly gemcitabine was administered at a rate of 50 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with a median dose of 63 Gy radiotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median age was 69 (range, 55-86). Median follow-up was 15 months (range, 5-53 months). A complete response was achieved in 12 patients (80%). Median progression free survival and overall survival were 15 months (range, 7-23 months) and 18 months (range not calculated), respectively. Local recurrence was found in 3 patients (20%) and distant recurrence was found in 5 patients (33.3%) for the entire group. While salvage surgery was performed on 1 patient, salvage chemotherapy was delivered for 4 patients. Treatment was well tolerated, there was no treatment interruption or instances of toxic death. A serious toxicity (grade 3) cystitis was seen in only 1 patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Multimodality treatment of muscle invasive BC proved a feasible and effective treatment option. Gemcitabine based chemoradiation is an active treatment option with a low toxicity profile for patients with muscle invasive BC, who are not suitable medically or refused to surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.147381","type":"journal-article","created":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T11:57:35Z","timestamp":1418903855000},"page":"704-707","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Radiotherapy concurrent with weekly gemcitabine after transurethral tumor resection in muscle \u0131nvasive bladder cancer"],"prefix":"10.4103","volume":"11","author":[{"given":"Umut","family":"Demirci","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dr. A.Y. Ankara Oncology Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"D\u0131zdar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Baskent University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Faik","family":"Cetindag","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Baskent University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Alt\u0131nova","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine, Baskent University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiye","family":"Ozsavran","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Baskent University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem Sener","family":"Dede","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Atat\u00fcrk Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurgul","family":"K\u0131z\u0131l\u0131rmak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Baskent University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Aysun","family":"Eraslan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Baskent University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Yalc\u0131n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Atat\u00fcrk Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havva Yesil","family":"Cinkir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. A.Y. Ankara Oncology Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","article-title":"Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: Long-term results in 1100 patients","volume":"61","author":"Hautmann","year":"2012","journal-title":"Eur Urol"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"R3-20260109","doi-asserted-by":"crossref","first-page":"v106","DOI":"10.1093\/annonc\/mdj963","article-title":"Challenges in the treatment of bladder cancer","volume":"17","author":"Kaufman","year":"2006","journal-title":"Ann Oncol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ncponc1159","article-title":"Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: Persisting uncertainties","volume":"5","author":"Choueiri","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"R6-20260109","first-page":"65","article-title":"Radiosensitization of human solid tumor cell lines with gemcitabine","volume":"23","author":"Shewach","year":"1996","journal-title":"Semin Oncol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2011.07.026","article-title":"Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer","volume":"102","author":"Borut","year":"2012","journal-title":"Radiother Oncol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijrobp.2008.08.021","article-title":"Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: Long-term results of a phase I trial","volume":"74","author":"Oh","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2004.10.070","article-title":"Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of a phase I trial","volume":"22","author":"Kent","year":"2004","journal-title":"J Clin Oncol"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/djq121","article-title":"Use of radical cystectomy for patients with invasive bladder cancer","volume":"102","author":"Gore","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","article-title":"Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Coppin","year":"1996","journal-title":"J Clin Oncol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1200\/JCO.2007.11.5287","article-title":"Antimetabolite radiosensitizers","volume":"25","author":"Shewach","year":"2007","journal-title":"J Clin Oncol"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12094-013-1047-8","article-title":"Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients","volume":"16","author":"Atasoy","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors","volume":"170","author":"Zietman","year":"2003","journal-title":"J Urol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:41Z","timestamp":1786647581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.147381","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}